NCT03165435撤回2 期
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Active Targeted Immunotherapy CV-MG01 in Patients With Moderate to Severe Myasthenia Gravis.
CuraVac2 个研究点 分布在 1 个国家开始时间: 2018年7月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 试验地点
- 2
- 主要终点
- Clinical efficacy
研究概览
简要总结
Study CV-0003 will be the second clinical trial administering CV-MG01 in humans. This will be a phase 2/3 proof-of-efficacy therapeutic confirmatory study following the proof-of-concept exploratory phase 1 study (CV-0002).
详细描述
The review of the clinical data accumulated so far in Study CV-0002 indicated that the safety and tolerability profile of CV-MG01 is considered very good, with positive immunogenicity results after the high dose regimen of CV-MG01. The preliminary results also show an indication of efficacy of CV-MG01, as based on the different scales and questionnaires results, all specific to MG disease. Therefore, it is proposed to investigate, in an appropriately designed, randomised, double-blind and powered study, the clinical efficacy of CV-MG01 in a larger cohort of MG patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female Patient, with generalised myasthenia gravis (Grades 2, 3 and 4a) as per myasthenia gravis foundation of America (MGFA) classification system.
- •Quantitative Myasthenia Gravis (QMG) score of 10 or greater at screening and baseline.
- •Age of minimum 18, at the time of the consent form signature.
- •Patient with documented positive antibodies to AChR in one of the available validated laboratory test.
- •Patient may use corticosteroid treatment initiated for at least 3 months before screening, equivalent to a daily dose of 30mg prednisone as maximum, and stable (+/- 5mg change) at least 1 month before the screening and up to the first injection.
- •Patient may use one or two immunosuppressive drugs (initiated for a least 6 months) with or without concomitant use of corticosteroid, providing that the dosage has been stable/unchanged for 3 months before the screening and up to the first injection.
- •Venous access sufficient to allow blood sampling as per the protocol.
- •Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
- •Have given written informed consent approved by the relevant Ethics Committee (EC) governing the site.
排除标准
- •MG patients of Grade 5 based on myasthenia gravis foundation of America (MGFA) classification.
- •Patients with history or presence of a primary or recurrent malignant disease including the presence or history of a thymoma.
- •Thymectomy planned during Part A of the study period or performed within 1 year prior to the first dose of study.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition not related to the treatment of MG, including human immunodeficiency virus (HIV) infection, or a family history of congenital or hereditary immunodeficiency.
- •History or evidence of administration of immunoglobulins and/or any blood products within 3 months prior to the first dose of study drug, or a planned administration of immunoglobulins during the first 3 months of the study.
- •History or evidence of rituximab treatment within 6 months prior to first dose of study.
- •History or evidence of plasmapheresis within 3 months prior to the first dose of study, or a planned plasmapheresis during the first 3 months of the study.
- •At high risk for aspiration.
- •Pulmonary: forced vital capacity reduced to less than 70% of predicted capacity.
- •History of severe allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- •History or evidence of Lambert-Eaton myasthenic syndrome, drug-induced myasthenia gravis, hereditary forms of myasthenic syndrome.
- •History of relevant chronic degenerative, psychiatric, or neurological disorder other than MG.
- •Severe hepatic, renal or cardiac insufficiency or uncontrolled hypertension
- •Major congenital defects or serious chronic illness other than MG.
- •Positive pregnancy test or desire to become pregnant during the study.
- •Female patients of child-bearing potential that do not use a reliable and highly effective method of contraception (see Section 7.2 Contraception) at least one month before first injection, during the study and until the end of Part A.
- •Any significant out-of-range Clinical Laboratory results considered as clinically significant and that prevent Subject's participation into the study according to Investigator's judgment.
- •Previous completion or withdrawal from this study or study CV-
- •Sponsor employees or Investigator site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
- •Any medical condition or concomitant medication that, in the opinion of the Investigator, might interfere with the subject's participation in the study, poses any added risk for the subject, or confounds the assessment of the subjects.
研究组 & 干预措施
Placebo
Placebo Comparator
Aluminium hydroxide adjuvant alone
干预措施: Placebo (Biological)
CV-MG01
Experimental
The active targeted immunotherapy candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis
干预措施: CV-MG01 (Biological)
结局指标
主要结局
Clinical efficacy
时间窗: 24 weeks
To assess the efficacy of 3 subcutaneous injections of CV-MG01 compared to placebo, as measured by a decrease from baseline of the QMG total score at 24 weeks after the first injection (equivalent to 12 weeks after last injection).
次要结局
- Safety (ohysical examens and laboratory tests) and local tolerance (FDA grading scale)(24 weeks)
- Efficacy - Responder rate(24 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic FibrosisCystic FibrosisNCT03375047Sanofi42
终止
2 期
A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRCMetastatic Colorectal Cancer (mCRC)NCT04856787Suzhou Suncadia Biopharmaceuticals Co., Ltd.62
已完成
1 期
Phase I/II Study of SRP-4053 in DMD PatientsDuchenne Muscular DystrophyNCT02310906Sarepta Therapeutics, Inc.39
进行中（未招募）
2 期
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)Alzheimer DiseaseNCT06427668Spinogenix24
已完成
2 期
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral CavitySquamous Cell Carcinoma of the Oral CavityNCT02873819Gliknik Inc.80